Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.
Haemangioblastoma is a rare, benign (grade I) vascular tumor of the CNS, often in cerebellum (80%), spine, or brainstem, comprising 2% of brain tumors. It’s highly vascular, cystic with mural nodule. Associated with von Hippel-Lindau (VHL) in 20-30%. In 2025, ~200-300 US cases, median age 30-40 for VHL-associated, 50 for sporadic.
Symptoms include headaches, nausea, vomiting, ataxia (balance loss), dizziness from cerebellar location; spinal cause pain, numbness, weakness. VHL may have retinal tumors, pheochromocytoma. In 2025, symptoms lead to MRI.
Causes include VHL gene mutations (tumor suppressor inactivation). Sporadic from somatic mutations. No environmental links. In 2025, angiogenesis (VEGF overexpression) is key.
Diagnosis uses MRI showing cystic mass with enhancing nodule, angiography for vascularity, and biopsy post-surgery. Genetic testing for VHL. In 2025, AI aids imaging.
Surgery is curative for sporadic (microsurgical resection), with embolisation for vascular tumors. Radiation (stereotactic) for unresectable. VHL requires surveillance. In 2025, anti-VEGF therapies reduce size.
In 2025, 10-year survival is 70-95%, better for complete resection. Recurrence 20% in VHL. By 2030, targeted VHL therapies could prevent multiplicity.
The information for haemangioblastoma is sourced from WebMD’s “Hemangioblastoma: Symptoms, Treatment, and More” for treatment; NCBI’s “Hemangioblastoma – StatPearls” for prognosis; Aaron Cohen-Gadol’s “Hemangioblastoma Symptoms | Expert Surgeon” for symptoms; Verywell Health’s “Hemangioblastoma: Survival, Symptoms, Causes, and More” for causes; Cleveland Clinic’s “Hemangioblastoma: Types, Radiology & Pathology” for types; Pacific Neuroscience Institute’s “Hemangioblastoma Treatment | Pacific Brain Tumor Center” for treatment; Columbia Neurosurgery’s “Hemangioblastoma Diagnosis & Treatment” for diagnosis; Aaron Cohen-Gadol’s “Hemangioblastoma Survival | Expert Surgeon” for survival; GARD’s “Hemangioblastoma | About the Disease” for disease; Medscape’s “Hemangioblastoma Treatment & Management” for management.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
1. Scan at your preferred center.
2. Written report from a specialist radiologist sent via email.
3. Access and download your scan images digitally.
4. Upon request, we can send the report and images to your doctor or hospital.
5. For self-referred patients, there is an additional charge of £30, which includes scan referral and a discussion with a private GP before and after the scan